个人中心 - 老虎社区

JoshuaQ

IP属地：未知

帖子 · 3帖子 · 3
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- JoshuaQJoshuaQ
  ·2021-04-16
  Latest
  4 Cathie Wood Stocks That Could Deliver Bigger Gains Than Tesla
  And they all have one key thing in common.
  4 Cathie Wood Stocks That Could Deliver Bigger Gains Than Tesla
  69 评论
  点赞
  分享
  举报
- JoshuaQJoshuaQ
  ·2021-04-16
  Latest
  If You Think AMC, Sundial, and Zomedica Are Cheap, I Have Bad News
  These ultra-popular Reddit stocks are fooling unsuspecting investors with their low share prices.
  If You Think AMC, Sundial, and Zomedica Are Cheap, I Have Bad News
  8 评论
  点赞
  分享
  举报
- JoshuaQJoshuaQ
  ·2021-04-16
  Latest
  What to watch today: Dow set to rise after closing above 34,000 for first time ever
  BY THE NUMBERS Dow futures rose modestlyFriday, a day after the30-stock averagegained nearly 1% andc
  What to watch today: Dow set to rise after closing above 34,000 for first time ever
  14 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3581565973970479","uuid":"3581565973970479","gmtCreate":1618471985068,"gmtModify":1618583334987,"name":"JoshuaQ","pinyin":"joshuaq","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/9d9719d9a331ff5138e098ddcb34f364","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":11,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":370847431,"gmtCreate":1618577199023,"gmtModify":1634291981191,"author":{"id":"3581565973970479","authorId":"3581565973970479","name":"JoshuaQ","avatar":"https://static.tigerbbs.com/9d9719d9a331ff5138e098ddcb34f364","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581565973970479","idStr":"3581565973970479"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/370847431","repostId":"2127664834","repostType":4,"repost":{"id":"2127664834","kind":"highlight","pubTimestamp":1618573860,"share":"https://ttm.financial/m/news/2127664834?lang=&edition=full","pubTime":"2021-04-16 19:51","market":"us","language":"en","title":"4 Cathie Wood Stocks That Could Deliver Bigger Gains Than Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=2127664834","media":"Motley Fool","summary":"And they all have one key thing in common.","content":"<p>Everyone knows that ARK Invest CEO Cathie Wood is a huge fan of <b>Tesla</b> (NASDAQ:TSLA). Elon Musk's company ranks as the top position in Wood's flagship exchange-traded fund, <b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a></b>. But Wood also likes several healthcare stocks. In this <i>Motley Fool Live</i> video <b>recorded on April 7</b>, Motley Fool contributors Keith Speights and Brian Orelli identify four healthcare stocks that are among Wood's top holdings that just might deliver bigger gains than Tesla.</p>\n<p><b>Keith Speights:</b> All right. Let's switch to a fun story, Brian. Now, you and I, we cover healthcare. We don't get to talk about stocks like Tesla very often, we just don't. We're going to talk about Tesla, kind of.</p>\n<p>Cathie Wood, famous investor, very well-known investor, highly followed investor. Her ARK Invest came out not long ago with a 2025 price target for Tesla that caused all kinds of controversy. It's way higher than Tesla's current price. They took a beating for predicting that Tesla's shares were going to really just skyrocket over the next few years.</p>\n<p>But Cathie Wood also likes quite a few healthcare stocks. I'm curious, Brian. Are there any of Cathie Wood's favorite healthcare stocks that you think could deliver bigger gains than Tesla will over the next five years?</p>\n<p><b>Brian Orelli:</b> Yeah. The only <a href=\"https://laohu8.com/S/AONE\">one</a> in the top holdings that I saw that I own is <b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX). It's big and in cystic fibrosis. Growth has been slowing down as it will treat more patients with its different medications. It's up to maybe three to four medications depending on how you count the combinations.</p>\n<p>It needs to find its next growth driver. There's plenty of pipeline candidates both internally developed, as well as licensed products. Among the licensed products, <b>CRISPR Therapeutics</b> (NASDAQ:CRSP) has a deal with the company. They have a treatment for beta-thalassemia and sickle cell that's already in clinical trials and has shown early efficacy, and then they have some earlier programs in Duchenne's muscular dystrophy, a disease called DM1, and cystic fibrosis.</p>\n<p>On the rest of her list, I really like <b>Regeneron</b> (NASDAQ:REGN). It's <a href=\"https://laohu8.com/S/AONE.U\">one</a> that I've always wished I owned, but it always seemed a little expensive. But that's the way good companies go sometimes and so sometimes, you just have to bite the bullet and buy it and I never did.</p>\n<p>If you're going to buy a large biotech company, you want to go for one with a lot of shots on goal and Regeneron has maybe almost the most shots on goal. It's really done well. I can't even think of Regeneron drug that has actually failed. I think maybe that's one of the reasons why it's doing well, even though it's had a really high price. Valuation is just because it's had so few failures, it's done really well at developing antibodies and being successful at that.</p>\n<p><b>Anything on the list that you saw?</b></p>\n<p><b>Speights:</b> Yeah. First, I would agree with you on both Vertex and Regeneron. The tickers there by the way are VRTX for Vertex and REGN for Regeneron. Yeah. When you're looking at big biotechs, those two are my favorites.</p>\n<p>Like you Brian, I own Vertex. I don't own Regeneron, but also like you, I wish I had bought it several years ago. Those are great picks that I do think both of those depending on how their pipeline candidates play out over the next few years, both of those stocks could potentially beat Tesla.</p>\n<p>I also like and own <b>Teladoc Health</b> (NYSE:TDOC). Ticker there is TDOC. That's another Cathie Wood favorite that she is very bullish on. I think Teladoc Health has been beaten down quite a bit over the last couple of months, but I think it's a stock that could very easily outperform Tesla over the next five years as virtual care really gains momentum.</p>\n<p>I will throw in a much riskier stock that I don't own, but just I've started doing a little research into. It's a stock called <b>Twist Bioscience</b> (NASDAQ:TWST). The ticker there is TWST. What Twist does is it makes synthetic DNA. The company offers next-generation sequencing products. It develops antibodies for biopharma companies, it's working on storing data and DNA.</p>\n<p>The market cap right now is only around $6 billion. They generated revenue of $90 million last year. It's priced at a premium, but investors are expecting great things from Twist Bioscience. Again, it's one of Cathie Wood's favorite biotech stocks and it's one that, like I said, is really risky, but it could pay off over the long run. It's one that I'm keeping my eye on.</p>\n<p><b>Orelli:</b> Twist just came on to my watchlist like in the last week.</p>\n<p><b>Speights:</b> Yeah.</p>\n<p><b>Orelli:</b> Because it was spurred on by this podcast. Luke Timmerman does a podcast called <i>The Long Run</i>, and the CEO, Emily Leproust was on the podcast. I'll put that link to that podcast in the chat. If anybody wants to get more information on Twist and what they're doing, I think that was a really interesting podcast.</p>\n<p><b>Speights:</b> Maybe sometime in the not-too-distant future, Brian, you and I can go a little deeper, dive into Twist Bioscience just to give our viewers more information about this biotech that's on both of our watchlists right now.</p>\n<p><b>Orelli:</b> Yeah, that sounds good.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Cathie Wood Stocks That Could Deliver Bigger Gains Than Tesla</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Cathie Wood Stocks That Could Deliver Bigger Gains Than Tesla\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 19:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/4-cathie-wood-stocks-that-could-deliver-bigger-gai/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Everyone knows that ARK Invest CEO Cathie Wood is a huge fan of Tesla (NASDAQ:TSLA). Elon Musk's company ranks as the top position in Wood's flagship exchange-traded fund, ARK Innovation ETF. But Wood...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/4-cathie-wood-stocks-that-could-deliver-bigger-gai/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/16/4-cathie-wood-stocks-that-could-deliver-bigger-gai/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127664834","content_text":"Everyone knows that ARK Invest CEO Cathie Wood is a huge fan of Tesla (NASDAQ:TSLA). Elon Musk's company ranks as the top position in Wood's flagship exchange-traded fund, ARK Innovation ETF. But Wood also likes several healthcare stocks. In this Motley Fool Live video recorded on April 7, Motley Fool contributors Keith Speights and Brian Orelli identify four healthcare stocks that are among Wood's top holdings that just might deliver bigger gains than Tesla.\nKeith Speights: All right. Let's switch to a fun story, Brian. Now, you and I, we cover healthcare. We don't get to talk about stocks like Tesla very often, we just don't. We're going to talk about Tesla, kind of.\nCathie Wood, famous investor, very well-known investor, highly followed investor. Her ARK Invest came out not long ago with a 2025 price target for Tesla that caused all kinds of controversy. It's way higher than Tesla's current price. They took a beating for predicting that Tesla's shares were going to really just skyrocket over the next few years.\nBut Cathie Wood also likes quite a few healthcare stocks. I'm curious, Brian. Are there any of Cathie Wood's favorite healthcare stocks that you think could deliver bigger gains than Tesla will over the next five years?\nBrian Orelli: Yeah. The only one in the top holdings that I saw that I own is Vertex Pharmaceuticals (NASDAQ:VRTX). It's big and in cystic fibrosis. Growth has been slowing down as it will treat more patients with its different medications. It's up to maybe three to four medications depending on how you count the combinations.\nIt needs to find its next growth driver. There's plenty of pipeline candidates both internally developed, as well as licensed products. Among the licensed products, CRISPR Therapeutics (NASDAQ:CRSP) has a deal with the company. They have a treatment for beta-thalassemia and sickle cell that's already in clinical trials and has shown early efficacy, and then they have some earlier programs in Duchenne's muscular dystrophy, a disease called DM1, and cystic fibrosis.\nOn the rest of her list, I really like Regeneron (NASDAQ:REGN). It's one that I've always wished I owned, but it always seemed a little expensive. But that's the way good companies go sometimes and so sometimes, you just have to bite the bullet and buy it and I never did.\nIf you're going to buy a large biotech company, you want to go for one with a lot of shots on goal and Regeneron has maybe almost the most shots on goal. It's really done well. I can't even think of Regeneron drug that has actually failed. I think maybe that's one of the reasons why it's doing well, even though it's had a really high price. Valuation is just because it's had so few failures, it's done really well at developing antibodies and being successful at that.\nAnything on the list that you saw?\nSpeights: Yeah. First, I would agree with you on both Vertex and Regeneron. The tickers there by the way are VRTX for Vertex and REGN for Regeneron. Yeah. When you're looking at big biotechs, those two are my favorites.\nLike you Brian, I own Vertex. I don't own Regeneron, but also like you, I wish I had bought it several years ago. Those are great picks that I do think both of those depending on how their pipeline candidates play out over the next few years, both of those stocks could potentially beat Tesla.\nI also like and own Teladoc Health (NYSE:TDOC). Ticker there is TDOC. That's another Cathie Wood favorite that she is very bullish on. I think Teladoc Health has been beaten down quite a bit over the last couple of months, but I think it's a stock that could very easily outperform Tesla over the next five years as virtual care really gains momentum.\nI will throw in a much riskier stock that I don't own, but just I've started doing a little research into. It's a stock called Twist Bioscience (NASDAQ:TWST). The ticker there is TWST. What Twist does is it makes synthetic DNA. The company offers next-generation sequencing products. It develops antibodies for biopharma companies, it's working on storing data and DNA.\nThe market cap right now is only around $6 billion. They generated revenue of $90 million last year. It's priced at a premium, but investors are expecting great things from Twist Bioscience. Again, it's one of Cathie Wood's favorite biotech stocks and it's one that, like I said, is really risky, but it could pay off over the long run. It's one that I'm keeping my eye on.\nOrelli: Twist just came on to my watchlist like in the last week.\nSpeights: Yeah.\nOrelli: Because it was spurred on by this podcast. Luke Timmerman does a podcast called The Long Run, and the CEO, Emily Leproust was on the podcast. I'll put that link to that podcast in the chat. If anybody wants to get more information on Twist and what they're doing, I think that was a really interesting podcast.\nSpeights: Maybe sometime in the not-too-distant future, Brian, you and I can go a little deeper, dive into Twist Bioscience just to give our viewers more information about this biotech that's on both of our watchlists right now.\nOrelli: Yeah, that sounds good.","news_type":1,"symbols_score_info":{"ARKIU":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":69,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":370847531,"gmtCreate":1618577176123,"gmtModify":1634291981313,"author":{"id":"3581565973970479","authorId":"3581565973970479","name":"JoshuaQ","avatar":"https://static.tigerbbs.com/9d9719d9a331ff5138e098ddcb34f364","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581565973970479","idStr":"3581565973970479"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/370847531","repostId":"2127342088","repostType":4,"repost":{"id":"2127342088","kind":"highlight","pubTimestamp":1618574220,"share":"https://ttm.financial/m/news/2127342088?lang=&edition=full","pubTime":"2021-04-16 19:57","market":"us","language":"en","title":"If You Think AMC, Sundial, and Zomedica Are Cheap, I Have Bad News","url":"https://stock-news.laohu8.com/highlight/detail?id=2127342088","media":"Motley Fool","summary":"These ultra-popular Reddit stocks are fooling unsuspecting investors with their low share prices.","content":"<p>For the past three months, it's not the pandemic that's been creating all the buzz on Wall Street. Rather, it's retail investors.</p>\n<p>Beginning in mid-January, retail investors on Reddit's WallStreetBets chatroom began banding together to buy shares and call options in stocks with very high levels of short interest. The goal of this strategy was to effect a short squeeze -- i.e., an event where short-sellers (pessimists) flee for the exit all at once, which can cause a rising share price to skyrocket higher.</p>\n<p>Quite a few of the stocks targeted by the Reddit community moved higher, with video game and accessories retailer <b>GameStop</b>&nbsp;representing the face of the retail movement.</p>\n<p><img src=\"https://static.tigerbbs.com/9be53e57590b1343cdbc68172a0bac01\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Bad news: Many of the most popular Reddit stocks are extremely pricey</h3>\n<p>But after three months of retail investors attempting to exert their influence in the market, <a href=\"https://laohu8.com/S/AONE\">one</a> thing has become crystal clear: Their assessment of what's \"cheap\" doesn't make a lot of sense.</p>\n<p>After perusing various social media sites, I've come across three ultra-popular Reddit stocks that the retail investment community believes are cheap or undervalued: movie-theater chain <b>AMC Entertainment</b> (NYSE:AMC), Canadian marijuana stock <b>Sundial Growers</b> (NASDAQ:SNDL), and clinical-stage veterinary drug and diagnostics company <b>Zomedica</b> (NYSEMKT:ZOM).</p>\n<p>While many of the reasons behind their supposed cheapness varies from company to company, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the few constants I've witnessed is the argument that their current share prices are significantly lower than their all-time highs. As of the closing bell on Monday, April 12, a share of AMC, Sundial, and Zomedica could be respectively purchased for $8.62, $0.93, and $1.12.</p>\n<p>For some context here, AMC shares traded north of $35 in late 2016. Meanwhile, Sundial and Zomedica have traded as high as $12 and $3, respectively, within the past couple of years.</p>\n<p>The issue with this argument is that share price alone provides no context into a company's relative valuation without taking outstanding shares into account.</p>\n<p><img src=\"https://static.tigerbbs.com/d9a9b323ff30faa3ac6ab8223b047381\" tg-width=\"700\" tg-height=\"461\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>For example, when AMC Entertainment's share price topped $35 in late 2016, its market cap neared, but never crossed, the $4 billion market-cap threshold. Today, with AMC's share price at $8.62, it boasts a market cap of close to $4.3 billion.</p>\n<p>Put another way, its share price has declined by around 75% since late 2016, but its market cap has grown by roughly 15%, all because the company's outstanding share count has ballooned higher. In reality, AMC has been historically <i>pricier</i> over the past two months than at any other time in its publicly traded history.</p>\n<p>The same can be said for Sundial. Shortly after it became a public company, shares of Sundial hit $12, equating to a $1.1 billion market cap. Today, shares of Sundial are going for $0.93, yet the market cap is around $1.54 billion.</p>\n<p>In less than two years, Sundial's share count has grown from less than 100 million to 1.66 billion outstanding. As a result, it's a pricier company now, at less than $1 a share, than it was when it had a $12 share price.</p>\n<p>To round things out, the same is true for Zomedica. In June 2018, when the company's share price quickly jumped to about $3, its market cap hit approximately $275 million. Today, with a $1.12 share price, Zomedica's market cap is nearly four times as high ($1.08 billion). In less than three years, Zomedica's outstanding share count has rocketed from a little over 90 million to 947.3 million. At no point in its history has Zomedica been this pricey.</p>\n<p><img src=\"https://static.tigerbbs.com/a7820c1f47b166de46066a8218fa6556\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>More bad news: They're fundamental and/or balance sheet disasters, too</h3>\n<p>To make matters worse, it's not just that retail investors are bypassing a company's outstanding share count when making a determination if it's cheap. They're also overlooking some very serious operating or balance sheet flaws.</p>\n<p>For instance, Zomedica was a clinical-stage company until the first commercial sale of its Truforma diagnostics system for companion animals in mid-March. Although Zomedica now has plenty of cash to fund its research for years to come, it's a billion-dollar stock that began generating revenue less than a month ago. This would seem to be an extremely aggressive valuation for a company that's nowhere near profitability.</p>\n<p>As for Sundial Growers, it has plenty of cash -- $719 million Canadian, or $572 million U.S. -- but its management team has no concrete plans how to use it. What's more, the company recently authorized an at-the-market program that could see another $800 million worth of shares sold. After issuing 1.15 billion shares in five months, Sundial isn't quite done pummeling its investors. And the icing on the cake is that the company is one of the slowest-growing in the cannabis space.</p>\n<p>Lastly, there's AMC, which I've argued is the most dangerous Reddit stock of all. Whereas Zomedica and Sundial each have a sizable net cash position, AMC is sitting on $11 billion in convertible and non-convertible debt. By 2026, $7.2 billion of this debt comes due, $6 billion of which can't be converted into shares. With the company unlikely to be profitable for years and strangled by its debt, it'll need shareholders to authorize a huge increase in its outstanding share count next month to have any chance at long-term survival.</p>\n<p>The point I'm trying to make is this: Operating results and balance sheets always matter. Getting too focused on one metric (short interest) while blatantly ignoring operating or balance sheet red flags can lead to disaster.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If You Think AMC, Sundial, and Zomedica Are Cheap, I Have Bad News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf You Think AMC, Sundial, and Zomedica Are Cheap, I Have Bad News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 19:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/16/if-you-think-amc-sundial-zomedica-cheap-bad-news/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the past three months, it's not the pandemic that's been creating all the buzz on Wall Street. Rather, it's retail investors.\nBeginning in mid-January, retail investors on Reddit's WallStreetBets ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/16/if-you-think-amc-sundial-zomedica-cheap-bad-news/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/16/if-you-think-amc-sundial-zomedica-cheap-bad-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127342088","content_text":"For the past three months, it's not the pandemic that's been creating all the buzz on Wall Street. Rather, it's retail investors.\nBeginning in mid-January, retail investors on Reddit's WallStreetBets chatroom began banding together to buy shares and call options in stocks with very high levels of short interest. The goal of this strategy was to effect a short squeeze -- i.e., an event where short-sellers (pessimists) flee for the exit all at once, which can cause a rising share price to skyrocket higher.\nQuite a few of the stocks targeted by the Reddit community moved higher, with video game and accessories retailer GameStop representing the face of the retail movement.\n\nImage source: Getty Images.\nBad news: Many of the most popular Reddit stocks are extremely pricey\nBut after three months of retail investors attempting to exert their influence in the market, one thing has become crystal clear: Their assessment of what's \"cheap\" doesn't make a lot of sense.\nAfter perusing various social media sites, I've come across three ultra-popular Reddit stocks that the retail investment community believes are cheap or undervalued: movie-theater chain AMC Entertainment (NYSE:AMC), Canadian marijuana stock Sundial Growers (NASDAQ:SNDL), and clinical-stage veterinary drug and diagnostics company Zomedica (NYSEMKT:ZOM).\nWhile many of the reasons behind their supposed cheapness varies from company to company, one of the few constants I've witnessed is the argument that their current share prices are significantly lower than their all-time highs. As of the closing bell on Monday, April 12, a share of AMC, Sundial, and Zomedica could be respectively purchased for $8.62, $0.93, and $1.12.\nFor some context here, AMC shares traded north of $35 in late 2016. Meanwhile, Sundial and Zomedica have traded as high as $12 and $3, respectively, within the past couple of years.\nThe issue with this argument is that share price alone provides no context into a company's relative valuation without taking outstanding shares into account.\n\nImage source: Getty Images.\nFor example, when AMC Entertainment's share price topped $35 in late 2016, its market cap neared, but never crossed, the $4 billion market-cap threshold. Today, with AMC's share price at $8.62, it boasts a market cap of close to $4.3 billion.\nPut another way, its share price has declined by around 75% since late 2016, but its market cap has grown by roughly 15%, all because the company's outstanding share count has ballooned higher. In reality, AMC has been historically pricier over the past two months than at any other time in its publicly traded history.\nThe same can be said for Sundial. Shortly after it became a public company, shares of Sundial hit $12, equating to a $1.1 billion market cap. Today, shares of Sundial are going for $0.93, yet the market cap is around $1.54 billion.\nIn less than two years, Sundial's share count has grown from less than 100 million to 1.66 billion outstanding. As a result, it's a pricier company now, at less than $1 a share, than it was when it had a $12 share price.\nTo round things out, the same is true for Zomedica. In June 2018, when the company's share price quickly jumped to about $3, its market cap hit approximately $275 million. Today, with a $1.12 share price, Zomedica's market cap is nearly four times as high ($1.08 billion). In less than three years, Zomedica's outstanding share count has rocketed from a little over 90 million to 947.3 million. At no point in its history has Zomedica been this pricey.\n\nImage source: Getty Images.\nMore bad news: They're fundamental and/or balance sheet disasters, too\nTo make matters worse, it's not just that retail investors are bypassing a company's outstanding share count when making a determination if it's cheap. They're also overlooking some very serious operating or balance sheet flaws.\nFor instance, Zomedica was a clinical-stage company until the first commercial sale of its Truforma diagnostics system for companion animals in mid-March. Although Zomedica now has plenty of cash to fund its research for years to come, it's a billion-dollar stock that began generating revenue less than a month ago. This would seem to be an extremely aggressive valuation for a company that's nowhere near profitability.\nAs for Sundial Growers, it has plenty of cash -- $719 million Canadian, or $572 million U.S. -- but its management team has no concrete plans how to use it. What's more, the company recently authorized an at-the-market program that could see another $800 million worth of shares sold. After issuing 1.15 billion shares in five months, Sundial isn't quite done pummeling its investors. And the icing on the cake is that the company is one of the slowest-growing in the cannabis space.\nLastly, there's AMC, which I've argued is the most dangerous Reddit stock of all. Whereas Zomedica and Sundial each have a sizable net cash position, AMC is sitting on $11 billion in convertible and non-convertible debt. By 2026, $7.2 billion of this debt comes due, $6 billion of which can't be converted into shares. With the company unlikely to be profitable for years and strangled by its debt, it'll need shareholders to authorize a huge increase in its outstanding share count next month to have any chance at long-term survival.\nThe point I'm trying to make is this: Operating results and balance sheets always matter. Getting too focused on one metric (short interest) while blatantly ignoring operating or balance sheet red flags can lead to disaster.","news_type":1,"symbols_score_info":{"AMC":0.9,"NWS":0.9,"SNDL":0.9,"ZOM":0.9}},"isVote":1,"tweetType":1,"viewCount":8,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":370844214,"gmtCreate":1618577116138,"gmtModify":1634291981780,"author":{"id":"3581565973970479","authorId":"3581565973970479","name":"JoshuaQ","avatar":"https://static.tigerbbs.com/9d9719d9a331ff5138e098ddcb34f364","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581565973970479","idStr":"3581565973970479"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/370844214","repostId":"1184644880","repostType":4,"repost":{"id":"1184644880","kind":"news","pubTimestamp":1618576781,"share":"https://ttm.financial/m/news/1184644880?lang=&edition=full","pubTime":"2021-04-16 20:39","market":"us","language":"en","title":"What to watch today: Dow set to rise after closing above 34,000 for first time ever","url":"https://stock-news.laohu8.com/highlight/detail?id=1184644880","media":"cnbc","summary":"BY THE NUMBERS\nDow futures rose modestlyFriday, a day after the30-stock averagegained nearly 1% andc","content":"<div>\n<p>BY THE NUMBERS\nDow futures rose modestlyFriday, a day after the30-stock averagegained nearly 1% andclosed above 34,000 for the first time ever. TheS&P 500increased 1.1% to another record close. ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/16/what-to-watch-dow-set-to-rise-after-closing-above-34000-for-first-time.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What to watch today: Dow set to rise after closing above 34,000 for first time ever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat to watch today: Dow set to rise after closing above 34,000 for first time ever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-16 20:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/16/what-to-watch-dow-set-to-rise-after-closing-above-34000-for-first-time.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BY THE NUMBERS\nDow futures rose modestlyFriday, a day after the30-stock averagegained nearly 1% andclosed above 34,000 for the first time ever. TheS&P 500increased 1.1% to another record close. ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/16/what-to-watch-dow-set-to-rise-after-closing-above-34000-for-first-time.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.cnbc.com/2021/04/16/what-to-watch-dow-set-to-rise-after-closing-above-34000-for-first-time.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1184644880","content_text":"BY THE NUMBERS\nDow futures rose modestlyFriday, a day after the30-stock averagegained nearly 1% andclosed above 34,000 for the first time ever. TheS&P 500increased 1.1% to another record close. TheNasdaqhad the best day, jumping 1.3% and finishing 0.4% away from its February closing record. Tech stocks rallied Thursday as the10-year Treasury yieldslippedbelow 1.6%. (CNBC)\n*'Roaring Kitty' stands to rake in millions on his GameStop options bet Friday(CNBC)\n*Dogecoin spikes 300% in a week, stoking fears of a cryptocurrency bubble(CNBC)\nMorgan Stanley(MS) this morning reportedbetter-than-expected earnings and revenuein the first quarter on strong bond trading results, following a week of stellar quarterly results to by financial firms. (CNBC)\n*PNC Financial dropped despite beat on earnings, revenue(Press Release)\n*Bank of New York Mellon shares rose after bank earnings, revenue beat(Press Release)\nBlowout March retail salesThursday helped lift stocks — and Friday, investors got a look at the red-hot residential real estate market. The Commerce Department saidMarch housing startssurged 19.4%, beating estimates. Building permits gained 2.7%, falling short of expectations. (CNBC)\n*'We need at least one more check' — the case for a fourth stimulus check(CNBC)\n*Cruise line CEOs press White House Covid team to resume sailings, sources say(CNBC)\n*American Eagle Outfitters CEO sees post-Covid 'Roaring 20s' for malls(CNBC)\nChina reported first-quarter gross domestic product a touch below expectations as industrial production disappointed but retail sales beat estimates.GDP soared 18.3%in Q1 from a year earlier. In the first quarter of 2020, the economy there shrank by 6.8% during the height of the domestic Covid outbreak. (CNBC)\nIN THE NEWS TODAY\nThe World Health Organization chief said Friday thatan alarming trendof rising Covid cases has resulted in infections around the world now approaching their highest level ever. In the U.S., cases per week are well off their all-time highs but consistent with levels seen during the summer surge. (CNBC)\nPfizer(PFE) CEO Albert Bourla said peoplewill likely needa booster dose of a Covid vaccine within 12 months of getting fully vaccinated. Bourla also said it’s possible that yearly vaccinations against the coronavirus will also be necessary. (CNBC)\n*Eli Lilly asks FDA to revoke authorization for Covid drug due to new variants (Reuters)\nAt least eight people diedafter a gunman opened fire at aFedExfacility in Indianapolis late Thursday and then killed himself, city police said. FedEx said in a statement: “We are deeply shocked and saddened by the loss of our team members. ... We are fully cooperating with investigating authorities.” (NBC News)\n*Video shows 13-year-old boy wasn’t holding gun when shot by Chicago police(AP)\n*Chauvin skips testifying as trial in George Floyd death nears end(AP)\n*Wright family demands more severe charges for Minnesota ex-officer(AP)\n*Critics condemn officer involved in Breonna Taylor raid writing a book(Louisville Courier Journal)\nPresident Joe Bidenis welcomingJapan’s prime minister to the White House on Friday in his first face-to-face meeting with a foreign leader, a choice that reflects Biden’s emphasis on strengthening alliances to deal with a more assertive China and other global challenges. (AP)\nThe National Football Leagueis officially openfor sports betting, announcing sportsbook partnerships with top companies Caesars (CZR), FanDuel, and DraftKings (DKNG). The agreements allow the sports betting firms to use NFL intellectual property and use its trademarks for betting promotions. (CNBC)\nHedge fund manager David Einhorn warned of dangers for retail investors that he sees in the stock market, and one of his main examples was a tiny New Jersey deli with a market cap of over $100 million. The Paulsboro, New Jersey-based store is the sole location for Hometown International(HWIN), with only $35,748 in sales in the last two years combined, according to securities filings.\n*NJ high school wrestling coach is CEO of $100 million firm that owns the deli(CNBC)\nShares of newly public cryptocurrency exchangeCoinbase (COIN) dipped in premarket trading on Friday. The weakness camedespite another vote of confidencefrom popular investor Cathie Wood, whose Ark Invest purchased about $110 million of the stock on Thursday. (Reuters)\nSTOCKS TO WATCH\nSunrun (RUN): Shares of the residential solar company jumped 3% after Simmons Energy upgraded the stock to an “overweight” rating. In a note to clients, the firm said the company has a strong growth story ahead, and that the recent weakness presents an attractive buying opportunity.\nCisco (CSCO): Cisco shares rose 1.1% in premarket trading Friday after Wolfe Research upgraded the equity to “outperform.” Analyst Jeff Kvaal wrote that “Strong  IT spending should prove a tailwind to Cisco  estimates” through fiscal year 2022 and said shares should climb to $63, representing a 22% upside from Thursday’s close.\nComcast (CMCSA): Shares of Comcast rose 1.2% before the opening bell after Raymond James upgraded the stock to an “outperform” rating and told clients it expects strong first-quarter earnings results from the media giant. “We believe there is future NBCU upside from HSD strength, Peacock sub growth, improved theatrical revenue, and phased theme park reopenings,” wrote analyst Frank Louthan.\nSimon Property Group (SPG): Shares of the real estate company rose in premarket trading after Jefferies upgraded the stock to “buy” from “hold.” The Wall Street firm said “retailer investments, pent-up consumer demand, and lower bad debt are positive catalysts” for the mall owner.\nUnited Airlines (UAL): Shares of the United Airlines popped in premarket trading following an upgrade to “buy” from “hold” from Argus. The Wall Street firm said it likes the airline’s plans to limit capacity, reduce structural costs by $2 billion, and restore margins to pre-pandemic levels.\nWATERCOOLER\nSo-called bucket list destinations come with big expectations — and often big crowds too. While overtourism can ruin many a holiday destination, it’s not the only reason vacations miss the mark. Here, travel writers who contribute to CNBC’s Global Travelershare the worst disappointmentsof their professional careers.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"SPY":0.9}},"isVote":1,"tweetType":1,"viewCount":14,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}